Determination of drug-related problems in the hematology service: a prospective interventional study.
Clinical pharmacist
Drug related problem
Hematologic malignancy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
received:
08
11
2023
accepted:
19
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
2
5
2024
Statut:
epublish
Résumé
Patients with hematological malignancies often require multidrug therapy using a variety of antineoplastic agents and supportive care medications. This increases the risk of drug-related problems (DRPs). Determining DRPs in patients hospitalized in hematology services is important for patients to achieve their drug treatment goals and prevent adverse effects. This study aims to identify DRPs by the clinical pharmacist in the multidisciplinary team in patients hospitalized in the hematology service of a university hospital in Turkey. This study was conducted prospectively between December 2022 and May 2023 in the hematology service of Suleyman Demirel University Research and Application Hospital in Isparta, Turkey. DRPs were determined using the Pharmaceutical Care Network Europe (PCNE) 9.1 Turkish version. This study included 140 patients. Older age, longer hospital stay, presence of acute lymphoblastic leukemia, presence of comorbidities, higher number of medications used, and polypharmacy rate were statistically significantly higher in the DRP group than in the non-DRP group (p < 0.05). According to multivariate logistic regression analysis, the probability of DRP in patients with polypharmacy was statistically significant 7.921 times (95% CI: 3.033-20.689) higher than in patients without polypharmacy (p < 0.001).Every 5-day increase in the length of hospital stay increased the likelihood of DRP at a statistically significant level (OR = 1.476, 95% CI: 1.125-1.938 p = 0.005). In this study, at least one DRP was detected in 69 (49.3%) patients and the total number of DRPs was 152. Possible or actual adverse drug events (96.7%) were the most common DRPs. The most important cause of DRPs was drug choice (94.7%), and the highest frequency within its subcategories was the combination of inappropriate drugs (93.4%). This study shows the importance of including a clinical pharmacist in a multidisciplinary team in identifying and preventing DRPs in the hematology service.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with hematological malignancies often require multidrug therapy using a variety of antineoplastic agents and supportive care medications. This increases the risk of drug-related problems (DRPs). Determining DRPs in patients hospitalized in hematology services is important for patients to achieve their drug treatment goals and prevent adverse effects. This study aims to identify DRPs by the clinical pharmacist in the multidisciplinary team in patients hospitalized in the hematology service of a university hospital in Turkey.
METHODS
METHODS
This study was conducted prospectively between December 2022 and May 2023 in the hematology service of Suleyman Demirel University Research and Application Hospital in Isparta, Turkey. DRPs were determined using the Pharmaceutical Care Network Europe (PCNE) 9.1 Turkish version.
RESULTS
RESULTS
This study included 140 patients. Older age, longer hospital stay, presence of acute lymphoblastic leukemia, presence of comorbidities, higher number of medications used, and polypharmacy rate were statistically significantly higher in the DRP group than in the non-DRP group (p < 0.05). According to multivariate logistic regression analysis, the probability of DRP in patients with polypharmacy was statistically significant 7.921 times (95% CI: 3.033-20.689) higher than in patients without polypharmacy (p < 0.001).Every 5-day increase in the length of hospital stay increased the likelihood of DRP at a statistically significant level (OR = 1.476, 95% CI: 1.125-1.938 p = 0.005). In this study, at least one DRP was detected in 69 (49.3%) patients and the total number of DRPs was 152. Possible or actual adverse drug events (96.7%) were the most common DRPs. The most important cause of DRPs was drug choice (94.7%), and the highest frequency within its subcategories was the combination of inappropriate drugs (93.4%).
CONCLUSIONS
CONCLUSIONS
This study shows the importance of including a clinical pharmacist in a multidisciplinary team in identifying and preventing DRPs in the hematology service.
Identifiants
pubmed: 38698336
doi: 10.1186/s12885-024-12291-w
pii: 10.1186/s12885-024-12291-w
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
552Informations de copyright
© 2024. The Author(s).
Références
Allart-Vorelli P, Porro B, Baguet F, Michel A, Cousson-Gélie F. Haematological cancer and quality of life: a systematic literature review. Blood cancer J. 2015;5(4):e305–e.
pubmed: 25909835
pmcid: 4450328
doi: 10.1038/bcj.2015.29
Westerweel PE, Te Boekhorst PA, Levin M-D, Cornelissen JJ. New approaches and treatment combinations for the management of chronic myeloid leukemia. Front Oncol. 2019;9:665.
pubmed: 31448223
pmcid: 6691769
doi: 10.3389/fonc.2019.00665
Alanazi F, Kwa FA, Burchall G, Jackson DE. New generation drugs for treatment of multiple myeloma. Drug Discov Today. 2020;25(2):367–79.
pubmed: 31765717
doi: 10.1016/j.drudis.2019.11.008
Wang L, Li L-r, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:1–23.
pubmed: 31900191
pmcid: 6942268
doi: 10.1186/s13045-020-01011-z
Kim MG, Jeong CR, Kim HJ, Kim JH, Song Y-K, Kim KI, et al. Network analysis of drug-related problems in hospitalized patients with hematologic malignancies. Support Care Cancer. 2018;26:2737–42.
pubmed: 29488017
doi: 10.1007/s00520-018-4106-4
Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383–9.
pubmed: 18686760
pmcid: 2546482
doi: 10.2147/CIA.S2468
Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187–95.
pubmed: 16939529
doi: 10.1111/j.1365-2125.2006.02744.x
Kaufmann CP, Stämpfli D, Hersberger KE, Lampert ML. Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. BMJ Open. 2015;5(3):e006376.
pubmed: 25795686
pmcid: 4368979
doi: 10.1136/bmjopen-2014-006376
Delpeuch A, Leveque D, Gourieux B, Herbrecht R. Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res. 2015;35(1):457–60.
pubmed: 25550587
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.
pubmed: 2316538
El Morabet N, Uitvlugt EB, van den Bemt BJ, van den Bemt PM, Janssen MJ, Karapinar-Çarkit F. Prevalence and preventability of drug‐related hospital readmissions: a systematic review. J Am Geriatr Soc. 2018;66(3):602–8.
pubmed: 29468640
doi: 10.1111/jgs.15244
Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41(2):192–9.
Reinau D, Furrer C, Stämpfli D, Bornand D, Meier CR. Evaluation of drug-related problems and subsequent clinical pharmacists’ interventions at a Swiss university hospital. J Clin Pharm Ther. 2019;44(6):924–31.
pubmed: 31408206
doi: 10.1111/jcpt.13017
Umar RM, Apikoglu-Rabus S, Yumuk PF. Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm. 2020;42:652–61.
pubmed: 32078106
doi: 10.1007/s11096-020-00992-8
Kara E, Okuyan B, Demirkan K, Sancar M. Question awaiting answer during the development and implementation stage of clinical pharmacy services in Turkey: who is clinical pharmacist? J Lit Pharm Sci. 2021;10(1):109–18.
doi: 10.5336/pharmsci.2020-76878
Law on Amending the Law on Pharmacists and Pharmacies and Certain Decree Laws. Official gazette of the Republic of Turkey, 29175, 14. Oct 2014. https://www.resmigazete.gov.tr/eskiler/2014/11/20141114-3.htm Accessed Sep 2023.
Albayrak A, Başgut B, Bıkmaz GA, Karahalil B. Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital. BMC Health Serv Res. 2022;22(1):1–7.
doi: 10.1186/s12913-022-07494-5
Hailu BY, Berhe DF, Gudina EK, Gidey K, Getachew M. Drug related problems in admitted geriatric patients: the impact of clinical pharmacist interventions. BMC Geriatr. 2020;20(1):1–8.
doi: 10.1186/s12877-020-1413-7
Ali MAS, Khedr EMH, Ahmed FAH, Mohamed NNE. Clinical pharmacist interventions in managing drug-related problems in hospitalized patients with neurological diseases. Int J Clin Pharm. 2018;40:1257–64.
pubmed: 29922968
doi: 10.1007/s11096-018-0658-0
Malfará M, Pernassi M, Aragon D, Carlotti A. Impact of the clinical pharmacist interventions on prevention of pharmacotherapy related problems in the paediatric intensive care unit. Int J Clin Pharm. 2018;40:513–9.
pubmed: 29603074
doi: 10.1007/s11096-018-0632-x
Chen P-Z, Wu C-C, Huang C-F. Clinical and economic impact of clinical pharmacist intervention in a hematology unit. J Oncol Pharm Pract. 2020;26(4):866–72.
pubmed: 31566112
doi: 10.1177/1078155219875806
Farias TF, Aguiar KS, Rotta I, Belletti KMS, Carlotto J. Implementing a clinical pharmacy service in hematology. Einstein (São Paulo). 2016;14:384–90.
pubmed: 27759828
doi: 10.1590/S1679-45082016AO3667
Visacri MB, Tavares MG, Barbosa CR, Duarte NC, Moriel P. Clinical pharmacy in onco-hematology and bone marrow transplant: a valuable contribution to improving patient safety. J Oncol Pharm Pract. 2021;27(5):1172–80.
pubmed: 32715916
doi: 10.1177/1078155220943964
De Grégori J, Pistre P, Boutet M, Porcher L, Devaux M, Pernot C, et al. Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department. J Oncol Pharm Pract. 2020;26(5):1172–9.
pubmed: 32299314
doi: 10.1177/1078155220915763
TUIK. The Results of Address Based Population Registration System. 2023. https://data.tuik.gov.tr/Bulten/Index?p=The-Results-of-Address-Based-Population-Registration-System-2023-49684&dil=2 . Accessed Feb 2024.
Raosoft Inc. (2004) RaoSoft® sample size calculator. http://www.raosoft.com/samplesize.html . Accessed Aug 2022.
UpToDate®. https://www.uptodate.com / Accessed Dec 2022.
Sandford J, Gilbert D, Mae Llering R, Sande M. Guide to antimicrobial therapy. Viena, Virginia: Antimicrobial therapy. Inc; 1997.
Uptodate Lexicomp Drugs & Drug Interaction. https://www.uptodate.com/home/drugs-drug-interaction Accessed Dec 2022.
Kovačević M, Vezmar Kovačević S, Miljković B, Radovanović S, Stevanović P. The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: a cross‐sectional study. Int J Clin Pract. 2017;71(10):e13005.
doi: 10.1111/ijcp.13005
Ren W, Liu Y, Zhang J, Fang Z, Fang H, Gong Y, et al. Prevalence of potential drug–drug interactions in outpatients of a general hospital in China: a retrospective investigation. Int J Clin Pharm. 2020;42:1190–6.
pubmed: 32488437
pmcid: 7476976
doi: 10.1007/s11096-020-01068-3
Luzze B, Atwiine B, Lugobe HM, Yadesa TM. Frequency, severity, and factors associated with clinically significant drug-drug interactions among patients with cancer attending Mbarara Regional Referral Hospital Cancer Unit, Uganda. BMC Cancer. 2022;22(1):1–11.
doi: 10.1186/s12885-022-10396-8
Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95.
pubmed: 22742913
doi: 10.1016/j.jclinepi.2012.02.018
Turner JP, Jamsen KM, Shakib S, Singhal N, Prowse R, Bell JS. Polypharmacy cut-points in older people with cancer: how many medications are too many? Support Care Cancer. 2016;24:1831–40.
pubmed: 26449548
doi: 10.1007/s00520-015-2970-8
Pharmaceutical Care Network Europe. PCNE classification V 9.1. https://www.pcne.org/workinggroups/2/drug-related-problem-classification . 2020;0. Accessed Dec 2022.
Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–22.
pubmed: 20418534
pmcid: 3227983
doi: 10.1634/theoncologist.2009-0290
Balducci L, Goetz-Parten D, Steinman MA. Polypharmacy and the management of the older cancer patient. Ann Oncol. 2013;24(Suppl 7):vii36–40.
pubmed: 24001761
pmcid: 6278993
doi: 10.1093/annonc/mdt266
Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257.
pubmed: 27843962
pmcid: 5084483
doi: 10.4103/2279-042X.192461
Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med. 2012;28(2):159–72.
pubmed: 22500536
doi: 10.1016/j.cger.2012.01.001
Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol. 1985;34(14):2549–53.
pubmed: 4015695
doi: 10.1016/0006-2952(85)90541-6
Lai C, Bhansali RS, Kuo EJ, Mannis G, Lin RJ. Older adults with newly diagnosed AML: hot topics for the practicing clinician. Am Soc Clin Oncol Educ Book. 2023;43:e390018.
pubmed: 37155946
doi: 10.1200/EDBK_390018
US Food and Drug Administration. Venetoclax tablets. 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208573s020s021lbl.pdf . Accessed Feb 2024.
BCCA protocol. Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax. 2022. http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Leukemia-BMT/ULKAMLAVEN_Protocol.pdf . Accessed Feb 2024.
Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69:999–1004.
pubmed: 22147077
doi: 10.1007/s00280-011-1797-3
San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11(1):51–61.
pubmed: 16401713
doi: 10.1634/theoncologist.11-1-51
Ho M, Moscvin M, Low SK, Evans B, Close S, Schlossman R, et al. Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. Leuk Lymphoma. 2022;63(10):2403–12.
pubmed: 35699975
pmcid: 9548493
doi: 10.1080/10428194.2022.2084729
US Food and Drug Administration. Bortezomi for Injection For subcutaneous or intravenous use. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021602s040lbl.pdf . Accessed Feb 2024.
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520.
pubmed: 31381464
doi: 10.1200/JCO.19.01461
Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452–67.
pubmed: 36638869
doi: 10.1016/j.annonc.2022.12.014
Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010;2(3):326–31.
pubmed: 21042495
pmcid: 2964764
doi: 10.4103/0975-1483.66807
Blower P, De Wit R, Goodin S, Aapro M. Drug–drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55(2):117–42.
pubmed: 15890526
doi: 10.1016/j.critrevonc.2005.03.007
Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65:757–73.
pubmed: 19543887
doi: 10.1007/s00228-009-0678-8
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–61.
pubmed: 18762933
doi: 10.1007/s00228-008-0553-z
Martins RR, Silva LT, Lopes FM. Impact of medication therapy management on pharmacotherapy safety in an intensive care unit. Int J Clin Pharm. 2019;41(1):179–88.
pubmed: 30552623
doi: 10.1007/s11096-018-0763-0
Lee C, Markarian A, Ladha F, Nakashima L, de Lemos M, Schaff K, et al. Real-world incidence of venetoclax toxicities in British Columbia. J Oncol Pharm Pract. 2022;28(5):1163–9.
pubmed: 35253497
doi: 10.1177/10781552221084616
Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, et al. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020;61(10):2383–8.
pubmed: 32449401
doi: 10.1080/10428194.2020.1768384
Li G-z, Hu Y-h, Li D-y, Zhang Y, Guo H-l, Li Y-m, et al. Vincristine-induced peripheral neuropathy: a mini-review. Neurotoxicology. 2020;81:161–71.
pubmed: 33053366
doi: 10.1016/j.neuro.2020.10.004
Ayhan YE, Karakurt S, Sancar M. The effect of the clinical pharmacist in minimizing drug-related problems and related costs in the intensive care unit in Turkey: a non‐randomized controlled study. J Clin Pharm Ther. 2022;47(11):1867–74.
pubmed: 36196779
doi: 10.1111/jcpt.13784